Please assess the completion status of the following clinical trial:

Trial Title: Meibomian Gland Dysfunction Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* evidence of meibomian gland obstruction in both eyes~* dry eye symptoms per DEQ-5~Exclusion Criteria:~* active ocular infection~* previous LipiFlow treatment~* beginning new oral or other systemic medications within prior 3 months~* beginning new or changing dosages of ocular medications within prior 3 months~* previous ocular surgery, trauma, herpes, recurrent inflammation, punctal plugs in prior 3 months~* habitual contact lens wear in prior 3 months~* women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subject Treatment (Type: EXPERIMENTAL): All subjects will receive light based (sham) treatment, then all subjects will receive LipiFlow treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).